Article
Pharmacogenetic studies: a tool to improve antidepressant therapy.
Drug metabolism and personalized therapy - 1 Dec 2016
Ramos Marta, Berrogain Cecilia, Concha Julia, Lomba Laura, García Cristina Belén, Ribate Mª Pilar
Abstract excerpt
The World Health Organization (WHO) predicts that major depressive disorder (MDD) will be the second leading cause of death and disability by 2020. Nowadays, approximately 60-70% of patients with this disorder have shown the lack of effectiveness and tolerability of the therapy with antidepressants. The US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) are including pharmacogenetic...
Topics
- Antidepressive Agents
- Depressive Disorder, Major
- Genotype
- Humans
- Pharmacogenetics